See more : Nitta Gelatin India Limited (NITTAGELA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of ICON Public Limited Company (ICLR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICON Public Limited Company, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Hwasung Industrial Co., Ltd. (002460.KS) Income Statement Analysis – Financial Results
- IL&FS Transportation Networks Limited (IL&FSTRANS.NS) Income Statement Analysis – Financial Results
- Avolta AG (DFRYF) Income Statement Analysis – Financial Results
- Stemsation International, Inc. (STSN) Income Statement Analysis – Financial Results
- JD Sports Fashion plc (JDDSF) Income Statement Analysis – Financial Results
ICON Public Limited Company (ICLR)
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.12B | 7.74B | 5.48B | 2.80B | 2.81B | 2.60B | 1.76B | 1.67B | 1.57B | 1.50B | 1.34B | 1.12B | 945.73M | 900.04M | 887.61M | 865.25M | 630.72M | 455.60M | 0.00 | 296.92M | 225.73M | 156.56M | 116.16M | 80.77M | 55.80M | 42.10M |
| Cost of Revenue | 5.72B | 5.53B | 3.97B | 1.99B | 1.97B | 1.83B | 1.03B | 961.33M | 908.98M | 903.17M | 845.41M | 718.13M | 611.92M | 541.39M | 507.78M | 489.24M | 354.48M | 256.26M | 0.00 | 162.56M | 122.37M | 83.37M | 63.80M | 42.04M | 29.30M | 0.00 |
| Gross Profit | 2.40B | 2.21B | 1.51B | 808.03M | 831.70M | 769.49M | 726.96M | 705.15M | 666.00M | 600.15M | 490.65M | 396.87M | 333.81M | 358.66M | 379.83M | 376.01M | 276.24M | 199.33M | 0.00 | 134.36M | 103.35M | 73.18M | 52.36M | 38.72M | 26.50M | 42.10M |
| Gross Profit Ratio | 29.56% | 28.60% | 27.52% | 28.89% | 29.64% | 29.64% | 41.34% | 42.31% | 42.29% | 39.92% | 36.72% | 35.59% | 35.30% | 39.85% | 42.79% | 43.46% | 43.80% | 43.75% | 0.00% | 45.25% | 45.79% | 46.75% | 45.08% | 47.94% | 47.49% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 319.28M | 317.00M | 318.56M | 322.27M | 332.90M | 308.74M | 277.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 6.74M | 7.17M | 4.51M | 3.56M | 5.20M | 3.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 776.36M | 778.75M | 585.33M | 341.69M | 336.75M | 325.79M | 323.74M | 325.73M | 326.79M | 336.46M | 313.93M | 280.78M | 255.86M | 232.69M | 230.91M | 248.78M | 187.99M | 136.57M | 0.00 | 88.81M | 71.12M | 48.95M | 36.31M | 27.35M | 18.00M | 0.00 |
| Other Expenses | 667.72M | 569.51M | 314.99M | 74.38M | 61.55M | 65.92M | 61.30M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 41.47M | 27.73M | 19.01M | 14.95M | 0.00 | 11.17M | 7.31M | 6.02M | 4.98M | 3.23M | 2.00M | 0.00 |
| Operating Expenses | 1.44B | 1.35B | 900.32M | 416.07M | 398.30M | 392.37M | 395.02M | 385.30M | 384.46M | 389.00M | 360.45M | 327.30M | 294.55M | 266.56M | 272.38M | 276.51M | 207.00M | 151.52M | 0.00 | 99.98M | 78.42M | 54.97M | 41.29M | 30.58M | 20.00M | 0.00 |
| Cost & Expenses | 7.16B | 6.88B | 4.87B | 2.41B | 2.37B | 2.22B | 1.43B | 1.35B | 1.29B | 1.29B | 1.21B | 1.05B | 906.47M | 807.95M | 780.16M | 765.74M | 561.48M | 407.78M | 0.00 | 262.54M | 200.80M | 138.34M | 105.09M | 72.62M | 49.30M | 0.00 |
| Interest Income | 5.01M | 2.35M | 574.00K | 2.72M | 6.86M | 4.76M | 2.35M | 1.48M | 1.31M | 1.15M | 986.00K | 1.15M | 1.19M | 1.76M | 752.00K | 2.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 336.70M | 229.73M | 182.42M | 15.07M | 6.42M | 13.61M | 12.99M | 13.01M | 3.99M | 785.00K | 1.29M | 1.97M | 1.64M | 1.13M | 3.53M | 4.11M | 0.00 | 0.00 | 0.00 | 281.00K | 0.00 | 0.00 | 0.00 | 575.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 585.95M | 614.73M | 360.33M | 94.61M | 91.92M | 65.92M | 61.25M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 32.66M | 27.73M | 18.89M | 14.84M | 0.00 | 10.60M | 7.27M | 5.97M | 4.96M | 3.23M | 2.00M | 0.00 |
| EBITDA | 1.52B | 1.41B | 739.43M | 488.83M | 532.19M | 451.76M | 401.94M | 379.43M | 339.21M | 263.69M | 168.67M | 111.09M | 69.32M | 127.73M | 140.86M | 130.11M | 88.25M | 62.77M | 0.00 | 31.94M | 45.55M | 32.23M | 24.23M | 16.05M | 8.50M | 42.10M |
| EBITDA Ratio | 18.74% | 18.57% | 16.85% | 17.48% | 17.64% | 17.22% | 19.33% | 23.26% | 21.54% | 18.13% | 13.90% | 10.18% | 9.28% | 14.00% | 15.87% | 15.04% | 13.99% | 13.78% | 0.00% | 15.34% | 14.28% | 15.48% | 13.82% | 16.09% | 15.23% | 100.00% |
| Operating Income | 956.15M | 795.24M | 608.47M | 391.97M | 433.41M | 377.12M | 331.95M | 311.69M | 281.54M | 202.35M | 121.17M | 69.57M | 29.44M | 92.10M | 107.45M | 99.50M | 69.24M | 47.82M | 0.00 | 34.38M | 24.93M | 18.21M | 11.08M | 8.15M | 6.50M | 42.10M |
| Operating Income Ratio | 11.78% | 10.27% | 11.10% | 14.01% | 15.45% | 14.53% | 18.88% | 18.70% | 17.88% | 13.46% | 9.07% | 6.24% | 3.11% | 10.23% | 12.11% | 11.50% | 10.98% | 10.50% | 0.00% | 11.58% | 11.04% | 11.63% | 9.53% | 10.09% | 11.65% | 100.00% |
| Total Other Income/Expenses | -331.69M | -227.39M | -181.85M | -10.30M | -6.42M | -8.74M | -10.28M | -11.52M | -2.69M | 366.00K | -302.00K | -796.00K | -448.00K | 629.00K | -2.78M | -1.22M | 2.74M | 3.64M | 0.00 | 979.00K | -9.10M | -5.60M | -4.62M | 2.52M | 2.60M | -32.49M |
| Income Before Tax | 624.47M | 567.85M | 196.68M | 382.18M | 426.99M | 368.38M | 327.67M | 300.17M | 278.85M | 202.72M | 120.87M | 68.70M | 29.00M | 92.72M | 104.67M | 98.28M | 71.98M | 51.46M | 0.00 | 34.67M | 25.28M | 19.33M | 13.60M | 9.19M | 9.10M | 0.00 |
| Income Before Tax Ratio | 7.69% | 7.34% | 3.59% | 13.66% | 15.22% | 14.19% | 18.63% | 18.01% | 17.71% | 13.48% | 9.05% | 6.16% | 3.07% | 10.30% | 11.79% | 11.36% | 11.41% | 11.29% | 0.00% | 11.68% | 11.20% | 12.35% | 11.70% | 11.38% | 16.31% | 0.00% |
| Income Tax Expense | 11.75M | 59.41M | 41.33M | 50.75M | 51.13M | 45.56M | 54.72M | 37.99M | 39.31M | 30.25M | 18.05M | 10.36M | 6.12M | 5.65M | 10.38M | 19.97M | 15.83M | 12.92M | 0.00 | 8.93M | 7.00M | 5.13M | 2.62M | 3.12M | 1.60M | 38.20M |
| Net Income | 612.34M | 505.30M | 153.19M | 327.81M | 373.99M | 322.82M | 272.94M | 262.18M | 239.54M | 172.47M | 102.81M | 58.35M | 22.88M | 87.07M | 94.30M | 78.12M | 55.96M | 38.30M | 0.00 | 25.74M | 18.28M | 14.20M | 10.98M | 6.07M | 7.50M | 3.90M |
| Net Income Ratio | 7.54% | 6.53% | 2.79% | 11.72% | 13.33% | 12.44% | 15.52% | 15.73% | 15.21% | 11.47% | 7.70% | 5.23% | 2.42% | 9.67% | 10.62% | 9.03% | 8.87% | 8.41% | 0.00% | 8.67% | 8.10% | 9.07% | 9.45% | 7.51% | 13.44% | 9.26% |
| EPS | 7.46 | 6.20 | 2.28 | 6.29 | 6.94 | 5.96 | 5.04 | 4.75 | 4.08 | 2.80 | 1.69 | 0.97 | 0.38 | 1.46 | 1.61 | 1.34 | 1.95 | 1.35 | 0.00 | 1.94 | 1.55 | 1.22 | 0.97 | 0.55 | 0.69 | 0.28 |
| EPS Diluted | 7.40 | 6.13 | 2.25 | 6.24 | 6.88 | 5.90 | 4.98 | 4.65 | 3.97 | 2.73 | 1.65 | 0.96 | 0.37 | 1.44 | 1.57 | 1.30 | 1.88 | 1.33 | 0.00 | 1.88 | 1.50 | 1.16 | 0.92 | 0.51 | 0.63 | 0.25 |
| Weighted Avg Shares Out | 82.10M | 81.53M | 67.11M | 52.86M | 53.86M | 54.12M | 54.13M | 55.25M | 58.75M | 61.50M | 60.91M | 59.97M | 60.38M | 59.72M | 58.64M | 58.25M | 28.71M | 28.31M | 13.86M | 13.27M | 11.81M | 11.66M | 11.29M | 11.05M | 10.91M | 13.93M |
| Weighted Avg Shares Out (Dil) | 82.72M | 82.47M | 68.07M | 53.28M | 54.33M | 54.74M | 54.87M | 56.41M | 60.29M | 63.13M | 62.25M | 60.68M | 61.07M | 60.64M | 59.90M | 60.22M | 29.75M | 28.86M | 13.86M | 13.70M | 12.18M | 12.24M | 11.94M | 11.82M | 11.92M | 15.92M |
Levi & Korsinsky Investigates Possible Securities Fraud Violations by ICON Public Limited Company (ICLR)
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
Levi & Korsinsky Announces an Investigation on Behalf of ICON Public Limited Company (ICLR) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
Levi & Korsinsky Investigates Possible Securities Fraud Violations by ICON Public Limited Company (ICLR)
NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
Shareholder Rights Advocates at Levi & Korsinsky Investigate ICON Public Limited Company (ICLR) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company's...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company's possible violations of federal securities laws. On October 23, 2024, Icon released...
Lost Money on ICON Public Limited Company (ICLR)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
ICON Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO , Nov. 15, 2024 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ICON Public Limited Company (NASDAQ: ICLR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely...
ICON Public Limited Company Being Investigated on Behalf of ICON Public Limited Company Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
The Law Offices of Frank R. Cruz Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a...
Source: https://incomestatements.info
Category: Stock Reports